胸部再程放疗临床与技术实践:ReCOG调查
胸部再程放疗全球应用增多但缺乏前瞻性证据,国际多学科专家在首届ReCOG会议上开展50题调查,34/51名专家回复。调查显示再程放疗目标包括延长局部控制与生存、缓解症状,主要担忧出血、气道损伤/瘘和食管溃疡/瘘,技术实践在图像配准、剂量累积与恢复因子方面存在差异,主要挑战为缺乏临床指南和软件支持工具。
要点
- 再程放疗目标为延长局部控制与生存、缓解/预防症状。
- 禁忌条件包括持续3级以上毒性和疾病进展。
- 主要毒性担忧为出血、气道损伤/瘘、食管溃疡/瘘。
核心结论
- 胸部再程放疗是日益受关注的领域,但前瞻性数据稀缺,目前主要关注治疗相关因素及如何与全身治疗联合。
研究设计与样本
- 由专家制定50题调查,在ReCOG胸部焦点组内讨论,涵盖人口学与临床经验、患者选择、影像与靶区、治疗计划及剂量累积。
- 调查完成者34/51名受邀专家,回复率67%。
主要发现
- 79%受访者为经验超过10年的物理师和放疗医师,65%主要来自大学医院。
- 最常见治疗肿瘤为局部复发肺癌、纵隔淋巴结或胸部转移灶。
- 再程放疗目标包括延长局部控制与生存、缓解/预防症状。
- 排除再程放疗的条件为持续3级以上毒性和疾病进展。
- 主要毒性担忧为出血、气道损伤/瘘和食管溃疡/瘘。
关键数值与推荐
- 技术实践在图像配准、剂量累积和恢复因子方面存在差异。
- 先进治疗计划技术和IGRT在受访者中一致应用。
临床怎么用
- 再程放疗决策需评估持续3级以上毒性和疾病进展作为禁忌。
- 需关注出血、气道损伤/瘘和食管溃疡/瘘等严重毒性风险。
- 应规范图像配准、剂量累积和恢复因子的技术流程。
局限性
- 调查回复率为67%,存在无应答偏倚可能。
- 缺乏前瞻性证据,实践主要基于机构经验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Thoracic reirradiation is increasingly used globally, but prospective evidence is scarce, leading to practice based primarily on institutional experience. Recognizing the need for guidance, international multi-professional experts convened at the first Reirradiation Collaborative Group (ReCOG) Meeting. This report presents results from a survey on best practices, challenges, and knowledge gaps among experts on thoracic reirradiation. METHODS: A comprehensive 50-question survey was developed by experts and discussed within the thoracic focus group at ReCOG. It included questions on participant demographics and clinical experience, patient-related clinical conditions and selection, imaging and targets, treatment planning, and dose accumulation. Participants were asked for perceived challenges as well as gaps in knowledge. RESULTS: The survey was completed by 34/51 invited experts (67 % response rate). Most respondents (79 %) were experienced physicists and radiation oncologists (>10 years) primarily at university hospitals (65 %). The most common tumors treated were locally recurrent lung cancer, mediastinal nodes, or thoracic metastases. Reirradiation goals included prolonging local control and survival, and alleviating/preventing symptoms. Conditions precluding reirradiation were persistent grade 3+ toxicity and progressive disease. Major toxicity concerns were bleeding, airway injury/fistula, and esophageal ulceration/fistula. Technical practices varied with regards to image registration, dose accumulation and recovery factors. Advanced treatment planning techniques and IGRT were consistent amongst respondents. Major challenges included lack of clinical guidelines and lack of software support tools. CONCLUSION: Thoracic reirradiation is an increasingly prevalent area of interest despite scarcity of prospective data. The major focus currently still is primarily on treatment-related factors and the question of how to combine reirradiation with systemic therapy. However, there is little guidance on whether and how to modify a planned reirradiation dose based on patient comorbidities or recovery from the prior radiation course. This survey identified emerging areas of consensus as well as relevant variations and gaps in practice.
引用
- Matuszak MM, Simone Ii CB, Matrosic CK, et al. Thoracic reirradiation clinical and technical practices: a survey from the reirradiation Collaborative Group (ReCOG). Clin Transl Radiat Oncol. 2025. PMID: 41049394. doi:10.1016/j.ctro.2025.101042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。